NPS on track in first quarter for 2013 Gattex goal
This article was originally published in Scrip
Executive Summary
Early prescription data for the NPS Pharmaceuticals drug Gattex (teduglutide) show that the company is making good progress toward its goal of having 200 to 300 short bowel syndrome (SBS) patients on therapy by the end of 2013.